Seragon Pharmaceuticals

Roche dumps lead asset from its $725M Seragon buy

Back in 2014, Roche spent $725 million upfront on California’s Seragon, but three years down the line, it has now canned work on its leading drug, ARN-810.

Ben Adams Apr 27, 2017 7:37am